Guardant Health Stock Performance
| GH Stock | USD 45.83 0.19 0.42% |
Guardant Health has a performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.07, which attests to a somewhat significant risk relative to the market. Guardant Health returns are very sensitive to returns on the market. As the market goes up or down, Guardant Health is expected to follow. Guardant Health right now retains a risk of 2.88%. Please check out Guardant Health sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to decide if Guardant Health will be following its current trending patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Guardant Health are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong technical indicators, Guardant Health is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return (1.76) | Five Day Return (5.31) | Year To Date Return 43.66 | Ten Year Return 41.74 | All Time Return 41.74 |
1 | Disposition of tradable shares by Joyce Meghan V. of Guardant Health subject to Rule 16b-3 | 05/02/2025 |
2 | Disposition of 23998 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | 05/13/2025 |
3 | Disposition of 8705 shares by Darya Chudova of Guardant Health subject to Rule 16b-3 | 05/15/2025 |
4 | Disposition of 44691 shares by AmirAli Talasaz of Guardant Health at 49.5337 subject to Rule 16b-3 | 05/16/2025 |
5 | Guardant Healths Shield Blood Test Gains NCCN Endorsement for Colorectal Cancer Screening GH ... | 06/02/2025 |
6 | Disposition of 1680 shares by AmirAli Talasaz of Guardant Health at 50.0041 subject to Rule 16b-3 | 06/05/2025 |
7 | Disposition of 8088 shares by Clark Ian T of Guardant Health subject to Rule 16b-3 | 06/12/2025 |
8 | Disposition of 250 shares by Tariq Musa of Guardant Health subject to Rule 16b-3 | 06/13/2025 |
9 | Disposition of 2626 shares by Potter Myrtle S of Guardant Health at 49.7 subject to Rule 16b-3 | 06/16/2025 |
10 | Guardant Health, Inc. Director Sells 158,947.11 in Stock | 06/23/2025 |
11 | Guardant Health Inc Trading 2.64 percent Higher on Jun 27 | 06/27/2025 |
12 | Disposition of 23997 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | 07/01/2025 |
13 | Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 | 07/14/2025 |
14 | Premier patient recrut pour ltude Vanguard du National Cancer Institute valuant le test Shield de dtection multicancer de Guardant Health | 07/15/2025 |
15 | Erster Patient erfolgreich in Vanguard-Studie des NCI rekrutiert, das den Shield-Multi-Cancer Detection Test von Guardant Health evaluiert | 07/16/2025 |
16 | Acquisition by Hidalgo Medina Manuel of 2784 shares of Guardant Health subject to Rule 16b-3 | 07/17/2025 |
| Begin Period Cash Flow | 1.1 B | |
| Total Cashflows From Investing Activities | -261.3 M |
Guardant Health Relative Risk vs. Return Landscape
If you would invest 4,564 in Guardant Health on April 23, 2025 and sell it today you would earn a total of 0.00 from holding Guardant Health or generate 0.0% return on investment over 90 days. Guardant Health is generating 0.0409% of daily returns and assumes 2.8849% volatility on return distribution over the 90 days horizon. Put differently, 25% of stocks are less risky than Guardant on the basis of their historical return distribution, and some 99% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
Guardant Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Guardant Health's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Guardant Health, and traders can use it to determine the average amount a Guardant Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0142
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GH |
Estimated Market Risk
| 2.88 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Guardant Health is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Guardant Health by adding it to a well-diversified portfolio.
Guardant Health Fundamentals Growth
Guardant Stock prices reflect investors' perceptions of the future prospects and financial health of Guardant Health, and Guardant Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Guardant Stock performance.
| Return On Equity | -45.84 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.54) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 6.36 B | ||||
| Shares Outstanding | 123.89 M | ||||
| Price To Earning | (12.01) X | ||||
| Price To Book | 55.67 X | ||||
| Price To Sales | 7.31 X | ||||
| Revenue | 739.02 M | ||||
| Gross Profit | 474.77 M | ||||
| EBITDA | (390.12 M) | ||||
| Net Income | (436.37 M) | ||||
| Cash And Equivalents | 853.69 M | ||||
| Cash Per Share | 8.35 X | ||||
| Total Debt | 1.34 B | ||||
| Debt To Equity | 4.32 % | ||||
| Current Ratio | 6.18 X | ||||
| Book Value Per Share | (2.03) X | ||||
| Cash Flow From Operations | (239.86 M) | ||||
| Earnings Per Share | (3.39) X | ||||
| Market Capitalization | 5.65 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | (2.58 B) | ||||
| Working Capital | 829.53 M | ||||
| Current Asset | 219.68 M | ||||
| Current Liabilities | 24.24 M | ||||
About Guardant Health Performance
By evaluating Guardant Health's fundamental ratios, stakeholders can gain valuable insights into Guardant Health's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Guardant Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Guardant Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 89.53 | 68.94 | |
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | 3.12 | 3.28 |
Things to note about Guardant Health performance evaluation
Checking the ongoing alerts about Guardant Health for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Guardant Health help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company generated the yearly revenue of 739.02 M. Annual Net Loss to common stockholders was (436.37 M) with gross profit of 474.77 M. | |
| Guardant Health reports about 853.69 M in cash with (239.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.35. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Erster Patient erfolgreich in Vanguard-Studie des NCI rekrutiert, das den Shield-Multi-Cancer Detection Test von Guardant Health evaluiert |
- Analyzing Guardant Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Guardant Health's stock is overvalued or undervalued compared to its peers.
- Examining Guardant Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Guardant Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Guardant Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Guardant Health's stock. These opinions can provide insight into Guardant Health's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |